title: Anthracycline-induced cardiomyopathy.
abstract: Anthracyclines are potent chemotherapeutic agents associated with 3 different forms of cardiomyopathy. Acute cardiomyopathy is seen within 3 months of drug exposure and may take the form of either a reversible myocarditis and pericarditis or an early-onset type and a late-onset type of chronic cardiomyopathy. Chronic anthracycline-induced cardiomyopathy is treated similarly to ischemic cardiomyopathies with beta-blockade and angiotensin-converting enzyme (ACE) inhibition. This review focuses on recent research regarding mechanisms of anthracycline-induced myocardial damage, the noninvasive imaging diagnosis of anthracycline-induced cardiomyopathy, and potential areas of future research regarding genetic screening and selecting individuals at increased risk, with consideration of prophylactic treatment with medications, specifically carvedilol and ACE inhibitors.
authors.affiliation: Division of Cardiovascular Diseases, University of Kansas School of Medicine, Kansas City, KS 66160, USA.
authors.forename: Ashley
authors.initials: A
authors.lastname: Simmons
authors.forename: James L
authors.initials: JL
authors.lastname: Vacek
authors.forename: David
authors.initials: D
authors.lastname: Meyers
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D006801:Humans
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents